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surgery in the Dutch health care setting. The hypothesis was that
higher drug costs for the tramadol/paracetamol combination
were offset by a reduction of costs associated with the treatment
of side-effects. METHODS: Decision analysis was used to model
the health economic outcomes. A cost-minimisation approach
was appropriate since the efﬁcacy of the two treatments proved
to be the same in the dosages used. Probabilities, resource utili-
sation data, and unit costs were obtained from published litera-
ture, Delphi panel and ofﬁcial price and tariff lists (Dutch costing
manual). The perspective taken was that of the health insurance.
RESULTS: The study showed that six days’ postoperative treat-
ment with the tramadol/paracetamol combination is cost saving
compared with codeine plus paracetamol and has fewer side-
effects (costs for tramadol/paracetamol: €42.46; codeine/parac-
etamol: €43.56). Sensitivity analyses conﬁrmed the robustness of
the model, with the tramadol/paracetamol combination being
similarly expensive or becoming the dominant strategy in 28 off
34 scenarios calculated. CONCLUSION: The results show that
postoperative pain therapy with the tramadol/paracetamol com-
bination is equally or less expensive and has fewer side effects
compared with a codeine/paracetamol combination, resulting in
favourable clinical and economic beneﬁts.
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OBJECTIVE: NeP pain is a devastating disorder that is likely to
compromise the patient’s quality of life. Generic tools are used
to measure impact of pain on health-related quality of life
(HRQoL) such as SF-12. The goal of this analysis was to assess
the reliability, concurrent and discriminant validity of SF-12 in
NeP or Mixed Pain (MP) patients. METHODS: Horizontal psy-
chometric properties were tested in a sample of 1519, with pain
for 1.1 + 2.8]patients [mean + SD; 56.0 + 13.7 years old (61,2%
female) years enrolled in an observational, prospective and mul-
ticenter study in NeP or MP patients of broad etiologies. Partic-
ipants completed a pain questionnaire (SF-MPQ), anxiety and
depression scales (Covi and Raskin), a disability inventory (SDS)
and the MOS-sleep questionnaire. RESULTS: Most patients
scored above 40mm on the SF-MPQ. Near 92% of patients com-
pleted the questionnaire. Test-retest reliability for both summary
components showed intraclass correlation coefﬁcients ranging
from 0.743 to 0.898 (p < 0.0001 in all cases). SF-12xs PCS was
able to distinguish between Nep and MP patients (adjusted mean
difference: 1.95 + 0.37; p < 0.0001), and levels of pain severity
(adjusted F = 4.91, p = 0.008), and disability (adjusted F = 7.15,
p < 0.0001). SF-12xs MCS showed its validity to differentiate
between patients with and without depression (adjusted mean
difference: 5.05 + 0.74; p < 0.0001). MCS & PCS showed con-
current correlations with anxiety (Covi; -0.21 to -0.43), depres-
sion (Raskin; -0.25 to -0.52), sleep disorders (MOS-sleep; -0.16
to -0.35) and disability (ShDS; -0.02 to -0.27). CONCLU-
SIONS: These results demonstrated the SF-12xs validity and reli-
ability as a measure of HRQoL in NeP patients.
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OBJECTIVE: Pain is associated with an important comorbidity,
related with sleep problems and mood disorders. This study was
aimed to describe the health status of patients according to pain
severity and symptom descriptors among patients with neuro-
pathic (NeP) or nociceptive pain (NoP). METHODS: We sur-
veyed 135 patients with pain (85 NeP and 50 NoP) of broad
origin attending three Pain Units. Patients completed the Short-
Form McGill Pain Questionnaire (SF-MPQ). Health status
(utility) was determined by means of the Health Utility Index
Mark 3 (HUI 3, Spanish version). Present Pain Intensity item
(PPI) of SF-MPQ was used to classiﬁed pain severity as mild, dis-
comforting, distressing, horrible and excruciating, and the 15
items of questionnaire to describe descriptors of pain. A descrip-
tor was considered absent in case of a score of 0, and present if
scoring ranged from 1 to 4. Analysis of covariance models and
multivariate regression were used. RESULTS: Mean (+ sem) age
was 62.6 + 1.3 years (range: 22–88) and 58% were female.
Eighty-seven percent were prescribed pain medications. Most
reported mild (22%), discomforting (36%) or distressing (24%)
pain, with 11% scoring the pain as horrible and 6% excruciat-
ing. Male and NoP patients were associated with poorer adjusted
HUI 3 scores: 0.41 + 0.04 (F = 4.22, p = 0.042) and 0.37 + 0.04
(F = 9.75, p = 0.002), respectively. Adjusted HUI 3 scores were
statistically associated with poorer PPI scoring: 0.66 + 0.05, 0.53
+ 0.04, 0.30 + 0.05, 0.20 + 0.09 and 0.39 + 0.15, respectively
(F = 8.33; p < 0.001). Tiring-exhausting and punishing-cruel
(affective symptoms) were both associated with lower HUI 3
scores: b-coefﬁcients; -0.149 (p = 0.010) and -0.171 (p = 0.005),
respectively. Health status was no associated with sensory symp-
toms descriptors. CONCLUSIONS: Present pain intensity and
presence of affective symptoms were both associated with a
poorer health status; the more severe the pain the more impaired
the health status, and was independent of age. Male and Noci-
ceptive Pain patients showed worst health status.
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OBJECTIVE: This work assessed the psychometric properties 
of the MOS-sleep scale in NeP syndromes. METHODS:
Psychometric properties were tested in NeP patients enrolled in
a naturalistic, prospective, multicenter study exploring the effec-
tiveness of gabapentin for 3 months. Participants completed
scales for pain (SF-McGill Pain Questionnaire), anxiety (Covi),
depression (Raskin), disability (Sheehan), and HRQoL (SF-12).
Feasibility, reliability, validity and sensitivity to change were
measured within this study. RESULTS: Six-hundred-three
patients [58.4 + 14.4 years (65.1% female), mean +, with pain
for 1.2 + 3.3 years were included. Pain intensity in a VAS
scored]SD 0–100 was 70.9 + 19.4 and in an ordinal item 0–5
was 2.8 + 1.1. The 10.9% of patients suffered neuropathies,
